Practical Considerations in the Modern Management of Small Cell Lung Cancer - AM2019
This course will discuss current evidence and emerging treatment options in the management of SCLC. An overview of small cell lung cancer (SCLC) will be provided including definitions, staging, epidemiology, pathology and ongoing clinical trials. The rationale for new systemic agents and immunotherapy will be reviewed. Pertinent controversies including the timing of radiation and commonly delivered dose fractionations in limited stage SCLC; as well as the merits of consolidative thoracic radiation and stereotactic radiotherapy in extensive stage SCLC will be discussed. Finally, the current role of prophylactic cranial irradiation (PCI) will be discussed in the context of emerging strategies such as hippocampal sparing PCI, MRI surveillance, immunotherapy and intracranial stereotactic radiotherapy.
The meeting is designed to meet the interests of radiation oncologists, medical oncologists, radiation physicists, nurses, surgeons, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, radiation biologists, and residents.
- Review the evidence for optimal dose and timing of radiotherapy for limited stage SCLC.
- Discuss the controversies of radiation in extensive stage (and oligometastatic) SCLC.
- Review the rationale for advanced radiation modalities, such as hippocampal-sparing prophylactic cranial irradiation and stereotactic radiotherapy.
The following persons served as faculty for this activity:
Alexander V Louie, MD, PhD, MSc, FRCPC is employed at Sunnybrook Odette Cancer Centre and receives compensation/remuneration/funding from AstraZeneca and Varian Medical Systems.
David Palma, MD, PhD is employed at London Health Sciences and also holds a U.S. Patent for CT method of imaging analysis after radiation.
Chad Rusthoven, MD is employed at the University of Colorado and received compensation/remuneration/funding from Genentech and Takeda.
Shankar Siva, PhD, MBBS, FRANZCR is employed at the University of Melbourne and receives compensation/remuneration/funding from Astellas, Astra Zeneca, Bristol Meyer Squibb, Roche Pharmaceuticals, and Varian Medical Systems.
Additionally, the Education and CME/MOC Committees had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.00 Certificate of AttendanceThis activity was designated for 1.00 AMA PRA Category 1 Credit™.
- 1.00 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.00 self-assessment credits.
- No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
- No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
- ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.